A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free…
AUNZ’s largest oncology research group, Breast Cancer Trials, today announced that their new trial for…
Seagen UK Ltd. today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA)…
It was announced today that the European Commission (EC) has granted marketing authorisation for tucatinib…
The U.S. Food and Drug Administration (FDA) approved tucatinib in combination with chemotherapy (trastuzumab and capecitabine)…
Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing…
Phase 1 clinical trial data published this week in the journal Clinical Cancer Research show early promise of…